Technical Analysis for HTBX - Heat Biologics, Inc.

Grade	Last Price	% Change	Price Change
	1.24	-3.88%	-0.05

HTBX closed down 3.88 percent on Friday, March 22, 2019, on 29 percent of normal volume.

ADX	Long-Term	Intermediate-Term	Short-Term
Weak or Absent	Down	Down	Down
See historical HTBX trend table...

Date	Alert Name	Type	% Chg
Mar 22	Wide Bands	Range Expansion	0.00%
Mar 21	Wide Bands	Range Expansion	-3.88%
Mar 20	Narrow Range Bar	Range Contraction	-0.80%
Mar 20	Wide Bands	Range Expansion	-0.80%
Mar 20	Oversold Stochastic	Weakness	-0.80%
Mar 19	Non-ADX 1,2,3,4 Bearish	Bearish Swing Setup	-2.36%
Mar 19	Wide Bands	Range Expansion	-2.36%
Mar 19	Oversold Stochastic	Weakness	-2.36%
Mar 18	Non-ADX 1,2,3,4 Bearish	Bearish Swing Setup	-4.62%
Mar 18	Stochastic Buy Signal	Bullish	-4.62%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company's products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; HS-410 for the bladder cancer treatment; HS-310 to treat ovarian cancer; and HS-510 for treating triple negative breast cancer. Its products also comprise HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.
Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Treatment Of Cancer Cancers Non Small Cell Lung Cancer Ovarian Cancer Vaccination HIV Cancer Treatment Platform Technology Vaccine Cancer Vaccine Treatment Of Non Small Cell Lung Cancer Biotechnology Companies Bladder Cancer Triple Negative Breast Cancer Chapel Hill Heat Biologics Neuvenge

Indicator	Bull Case	Neutral / Hold	Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary:	Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Date	Title
Mar 21	Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy
Mar 11	HTBX: HS-110 Interim Update
Mar 5	Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai
Mar 1	Healthcare and Tech dominate midday movers
Mar 1	Puma Biotechnology and Lexicon Pharmaceuticals among healthcare gainers; ImmunoGen leads the losers
Mar 1	NTNX and WUBA among premarket losers
Feb 28	Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium
Feb 28	The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems
Feb 26	54 Stocks Moving In Tuesday's Mid-Day Session
Feb 26	Mallinckrodt and Aerie Pharmaceuticals among healthcare gainers; Celldex Therapeutic and Conformis among losers

Pivot Point Level	Traditional / Classic	Fibonacci	Demark	Woodie	Camarilla
Resistance 4 (R4)					1.35
Resistance 3 (R3)	1.36	1.33			1.34
Resistance 2 (R2)	1.33	1.31		1.33	1.33
Resistance 1 (R1)	1.29	1.29	1.27	1.28	1.32
Pivot Point	1.26	1.26	1.25	1.25	1.26
Support 1 (S1)	1.21	1.23	1.20	1.20	1.16
Support 2 (S2)	1.18	1.21		1.18	1.15
Support 3 (S3)	1.14	1.18			1.15
Support 4 (S4)					1.13